Health & Wellness for a LIFETIME
1581 Route 202 Pacesetter Park
Pomona, NY 10970
845-354-7621
Archive:
- 2012
- January (11)
- PFC Lowers Antibodies!
- People Don't Stop Smoking After Seing Plaque in Carotids!
- Pharmaceutical Companies and Physicians
- Importance of Vitamin D
- Statin Drugs and Diabetes
- Heart Attacks and Long Distance Running
- Wasted Research Money?
- Nicotine Patch Ineffective
- So How Much Exercise Can You Squeeze In?
- Neti-Pot Problems
- AHA Study: Heart Disease Increasing
- 2011
- December (11)
- Cranberries vs. Antibiotics for UTI
- Antioxidants Reduce Cancer Risk
- Back Surgery: Too Many, Too Costly, Too Ineffective!
- Simvastin (Zocor, Vytorin, Simcor) Danger
- Physicians Rate Insurance Companies
- Anti-coagulant Drug Problems
- Bad News about Stop Smoking Drug
- Antibiotics: Inappropriately Used
- Exercise More Important Than BMI
- Pediatric Antibiotis: Over Prescribed?
- FDA Criticized Dr. Oz But Was It Fair?
Tags
Categories:
FDA Investigating Serious Bleeding Events with Dabigatra
The FDA is investigating serious bleeding events with the anticoagulant dabigatran (marketed as Pradaxa) but maintains that for now, the drug's benefits "continue to exceed the potential risks" when it is used according to the prescribing information.
The agency says that while "even fatal" bleeding events have been reported since dabigatran was approved for reducing risks for stroke in patients with nonvalvular atrial fibrillation, it remains to be seen whether the rate is higher than would be expected.
Providers should continue prescribing the drug according to its approved label, the FDA says.Coming soon.
Comment: Why does the FDA continue to approve drugs, then find problems with them after they are on the market and result in either health issues or death?